ECM
HAE icon

ExodusPoint Capital Management’s Haemonetics HAE Stock Holding History

ExodusPoint Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$1.75M – 2115
2020
Q3 		$1.75M Buy
+20,000
New +$1.75M 0.03% 447

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ExodusPoint Capital Management's HAE Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Haemonetics (HAE) stake by 50% in Q1 2026, selling an estimated $3.16M and leaving 47,750 shares worth $2.69M. The position accounts for 0.02% of the portfolio, ranked #655.

ExodusPoint Capital Management first reported a position in HAE in Q4 2019 and has held it in 17 quarters since. The position peaked at $15.2M in Q3 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • ExodusPoint Capital Management held 47,750 shares of Haemonetics worth $2.69M as of Q1 2026.
  • ExodusPoint Capital Management sold 48,568 Haemonetics shares in Q1 2026, an estimated $3.16M.
  • Haemonetics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #655 holding.
  • ExodusPoint Capital Management first reported a position in Haemonetics in Q4 2019 and has held it in 17 quarters since.
  • ExodusPoint Capital Management's Haemonetics position peaked at $15.2M in Q3 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.